The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of the PI3Kδ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).
 
John M. Pagel
Consulting or Advisory Role - Actinium Pharmaceuticals; AstraZeneca; BeiGene; Epizyme; Gilead Sciences; Loxo; MEI Pharma; MorphoSys; TG Therapeutics
 
Nishitha Reddy
Honoraria - Celgene; Morphosys
 
Deepa Jagadeesh
Consulting or Advisory Role - Atara Biotherapeutics; Kyowa Hakko Kirin; Verastem
Speakers' Bureau - Verastem
Research Funding - ADC Therapeutics (Inst); AstraZeneca (Inst); Debiopharm Group (Inst); MEI Pharma (Inst); MEI Pharma (Inst); Regeneron (Inst); Rhizen Pharmaceuticals (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Trillium Therapeutics (Inst)
 
Anastasios Stathis
Consulting or Advisory Role - Bayer (Inst); Lilly (Inst)
Research Funding - ADC Therapeutics (Inst); Bayer (Inst); Cellestia Biotech (Inst); Lilly (Inst); MEI Pharma (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Abbvie; PharmaMar
 
Adam Steven Asch
Research Funding - Astellas Pharma (Inst); Cartesian Therapeutics (Inst); Forty Seven (Inst); Juno Therapeutics (Inst); Macrogenics (Inst); MEI Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Provisional patent submitted (I)
 
Huda S. Salman
No Relationships to Disclose
 
Vaishalee Padgaonkar Kenkre
No Relationships to Disclose
 
Jacob Drobnyk Soumerai
Consulting or Advisory Role - Abbvie; AstraZeneca; BeiGene; Bristol-Myers Squibb; TG Therapeutics
Research Funding - Adaptive Biotechnologies; BeiGene; BostonGene; Genentech/Roche; GlaxoSmithKline; TG Therapeutics
 
Judith Llorin-Sangalang
Employment - MEI Pharma
Research Funding - MEI Pharma
Travel, Accommodations, Expenses - MEI Pharma
 
Igor Gorbatchevsky
Employment - Bayer; Iovance Biotherapeutics; MEI Pharma
 
Joanne Li
Employment - MEI Pharma
Stock and Other Ownership Interests - Amgen; Lilly
 
Andrew David Zelenetz
Honoraria - Clinical Care Options; NCCN; Oncology Information Group; PER; Plexus
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Celgene; Coherus Biosciences; Curio Science; Curis; Dava Oncology; Debiopharm Group; Genentech/Roche; Gilead Sciences; Juno/Celgene/Bristol-Myers Squibb; Karyopharm Therapeutics; Kite, a Gilead company; MEI Pharma; MorphoSys; Pharmacyclics; Quant Health; Seagen; Vaniam Group; Verastem
Research Funding - BeiGene; Genentech/Roche; Gilead Sciences; MEI Pharma